TW202328178A - 抗Aβ初原纖維抗體的皮下配製物及其使用方法 - Google Patents

抗Aβ初原纖維抗體的皮下配製物及其使用方法 Download PDF

Info

Publication number
TW202328178A
TW202328178A TW111132756A TW111132756A TW202328178A TW 202328178 A TW202328178 A TW 202328178A TW 111132756 A TW111132756 A TW 111132756A TW 111132756 A TW111132756 A TW 111132756A TW 202328178 A TW202328178 A TW 202328178A
Authority
TW
Taiwan
Prior art keywords
subject
pharmaceutical composition
seq
dose
week
Prior art date
Application number
TW111132756A
Other languages
English (en)
Chinese (zh)
Inventor
小山彰比古
查德 史旺森
道夫 金清
米雪兒 愛里沙瑞
琳恩 卡莫
珍 卡普洛
大衛 維貝爾
薩布哈 達哈達
帕拉宜 薩迪夫
拉里薩 瑞德曼
伊瑄妮 蘭德瑞
早戶誠一
羅伯特 戈登
Original Assignee
日商衛材R&D企管股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商衛材R&D企管股份有限公司 filed Critical 日商衛材R&D企管股份有限公司
Publication of TW202328178A publication Critical patent/TW202328178A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW111132756A 2021-08-30 2022-08-30 抗Aβ初原纖維抗體的皮下配製物及其使用方法 TW202328178A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202163260730P 2021-08-30 2021-08-30
US63/260,730 2021-08-30
US202263306050P 2022-02-02 2022-02-02
US63/306,050 2022-02-02
US202263269389P 2022-03-15 2022-03-15
US63/269,389 2022-03-15
US202263269463P 2022-03-16 2022-03-16
US63/269,463 2022-03-16
US202263364619P 2022-05-12 2022-05-12
US63/364,619 2022-05-12

Publications (1)

Publication Number Publication Date
TW202328178A true TW202328178A (zh) 2023-07-16

Family

ID=83438517

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111132756A TW202328178A (zh) 2021-08-30 2022-08-30 抗Aβ初原纖維抗體的皮下配製物及其使用方法

Country Status (9)

Country Link
US (1) US20240352109A1 (cg-RX-API-DMAC7.html)
EP (1) EP4395821A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024532438A (cg-RX-API-DMAC7.html)
KR (1) KR20240053620A (cg-RX-API-DMAC7.html)
AU (1) AU2022338055A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230148A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024002567A (cg-RX-API-DMAC7.html)
TW (1) TW202328178A (cg-RX-API-DMAC7.html)
WO (1) WO2023034230A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025030769A1 (zh) * 2023-08-10 2025-02-13 浙江格物致知生物科技有限公司 一种辅助诊断阿尔茨海默病的联检试剂盒及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL324807A (en) * 2023-06-09 2026-01-01 Eisai R&D Man Co Ltd Treatment methods using anti-Abeta protofibril antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
SI2448968T1 (sl) 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
KR102630042B1 (ko) * 2016-10-27 2024-01-29 에자이 알앤드디 매니지먼트 가부시키가이샤 알츠하이머병의 치료를 위한 항-a베타 원시섬유 항체 및 베타-세크레타제 bace1 억제제를 포함하는 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025030769A1 (zh) * 2023-08-10 2025-02-13 浙江格物致知生物科技有限公司 一种辅助诊断阿尔茨海默病的联检试剂盒及应用

Also Published As

Publication number Publication date
AU2022338055A1 (en) 2024-02-29
MX2024002567A (es) 2024-03-20
EP4395821A1 (en) 2024-07-10
JP2024532438A (ja) 2024-09-05
KR20240053620A (ko) 2024-04-24
WO2023034230A1 (en) 2023-03-09
CA3230148A1 (en) 2023-03-09
US20240352109A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
TW202317192A (zh) 用於阿茲海默氏症治療的生物標記物
TW202430554A (zh) 使用tau PET水平之治療方法
JP2024509960A (ja) 抗アミロイドベータ抗体及びその使用
TW202334201A (zh) 抗Tau抗體之組成物、劑型及方法
TW202339794A (zh) 使用p—tau181水平之治療方法
US20240352109A1 (en) Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
CN110214146B (zh) 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物
TWI894689B (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
US20250051427A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
TW202313111A (zh) 治療阿茲海默症之方法
CN117999094A (zh) 抗Aβ初原纤维抗体的皮下配制品及其使用方法
AU2015254661A9 (en) Treatment and prevention of Alzheimer's Disease (AD)
AU2015254663B2 (en) Treatment and prevention of Alzheimer's Disease (AD)
KR20260022396A (ko) 항-Aβ 프로토피브릴 항체를 사용한 치료 방법
EA052963B1 (ru) Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку
WO2026075947A1 (en) Dosing regimens for early alzheimer's disease
EA051320B1 (ru) Способ безопасного введения антитела к тау-белку
TW202019471A (zh) 阿茲海默症之治療及預防方法
CN116059340A (zh) 用于治疗复发形式的多发性硬化的方法